At the news
? BEARISHIMPACT 6/10 PRESS-RELEASE filed Mar 17, 2026 at 16:01 ET
SAB Biotherapeutics (SABS) has announced the commencement of an underwritten public offering of common stock and pre-funded warrants, with an option for underwriters to purchase up to an additional 15%. The company intends to use the proceeds to fund clinical development of its lead candidate, SAB-142, for type 1 diabetes, along with manufacturing, regulatory activities, and general corporate purposes. The offering is subject to market conditions, and no specific size, price, or terms have been disclosed.
- SAB Biotherapeutics (SABS) has commenced an underwritten public offering of common stock and pre-funded warrants.
- Underwriters have a 30-day option to purchase up to an additional 15% of the securities offered.
- All securities are being sold by the company, indicating dilution for existing shareholders.
- Proceeds will be used to fund development of SAB-142 through clinical trials, manufacturing, regulatory activities, and general corporate purposes.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access